CN106420772A - 一种治疗急性胰腺炎的药物组合物 - Google Patents
一种治疗急性胰腺炎的药物组合物 Download PDFInfo
- Publication number
- CN106420772A CN106420772A CN201610819356.7A CN201610819356A CN106420772A CN 106420772 A CN106420772 A CN 106420772A CN 201610819356 A CN201610819356 A CN 201610819356A CN 106420772 A CN106420772 A CN 106420772A
- Authority
- CN
- China
- Prior art keywords
- acute pancreatitis
- pharmaceutical composition
- steroid
- medicinal composition
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 24
- 206010033647 Pancreatitis acute Diseases 0.000 title claims abstract description 22
- 201000003229 acute pancreatitis Diseases 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 8
- 150000003431 steroids Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108090000913 Nitrate Reductases Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- -1 correctivess Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610819356.7A CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610819356.7A CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106420772A true CN106420772A (zh) | 2017-02-22 |
CN106420772B CN106420772B (zh) | 2017-07-28 |
Family
ID=58167664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610819356.7A Active CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106420772B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102408466A (zh) * | 2011-12-22 | 2012-04-11 | 江苏省中国科学院植物研究所 | 一种新盐角草皂苷及其制备方法和用途 |
CN102558278A (zh) * | 2010-12-28 | 2012-07-11 | 复旦大学 | 三萜类化合物及其在制备抗补体药物中的用途 |
-
2016
- 2016-09-13 CN CN201610819356.7A patent/CN106420772B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102558278A (zh) * | 2010-12-28 | 2012-07-11 | 复旦大学 | 三萜类化合物及其在制备抗补体药物中的用途 |
CN102408466A (zh) * | 2011-12-22 | 2012-04-11 | 江苏省中国科学院植物研究所 | 一种新盐角草皂苷及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106420772B (zh) | 2017-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3149460A1 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
CN106232109A (zh) | 包含棉酚和苯乙双胍作为活性成分的用于癌症治疗的药物组合物 | |
CN108136217A (zh) | 用于治疗膀胱癌的制剂 | |
CN104363899A (zh) | [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的增溶的胶囊制剂 | |
CN103720701A (zh) | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 | |
CN114306236B (zh) | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 | |
CN110352058A (zh) | 相伴给予糖皮质激素受体调节剂和cyp3a抑制剂 | |
CN105125495B (zh) | 聚酯类材料担载双硫仑的纳米粒及其应用、药物制剂及其应用 | |
KR101949810B1 (ko) | 설폰아마이드류 약학 조성물 | |
CN102716184A (zh) | 一种中药组合物及其应用 | |
CN108686216A (zh) | 包含化学消融剂和生物活性多糖的药物组合物及其用途 | |
CN104825402B (zh) | 一种含有吉西他滨的注射用药物组合物 | |
CN106420772A (zh) | 一种治疗急性胰腺炎的药物组合物 | |
CN1729988A (zh) | 磷酸肌酸钠和镁盐的组合药物 | |
CN101678017A (zh) | 治疗糖尿病的方法 | |
CN104940181B (zh) | β‑羟丁酸或其药学上可接受的盐的用途 | |
KR101893812B1 (ko) | 13가지 글리세리드를 포함한 의이인오일, 제제 및 그 응용 | |
CN102973941A (zh) | 包载化疗药物的聚合物水凝胶及其在预防肿瘤复发和防治术后腹腔粘连中的用途 | |
Fearon et al. | An energy and protein dense, high n-3 fatty acid oral supplement promotes weight gain in cancer cachexia | |
DE212020000727U1 (de) | Zusammensetzung mit Wirkstoff-enthaltenden Mikro-Nano-Partikeln eines Wirkstoffs gegen Krebs | |
CN108685926A (zh) | 包含化学消融剂和生物活性苷的药物组合物及其用途 | |
CN1775208A (zh) | 由水飞蓟素制备的益肝灵制剂及其制备方法 | |
US10688128B2 (en) | Use of Z-butylidenephthalide in activating autoimmune system | |
CN106619613A (zh) | 白果内酯作为脑靶向增效剂在制备防治脑肿瘤药物的应用 | |
CN105832730A (zh) | 氯唑西林钠和克霉唑的组合物及其在生物医药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Lei Inventor after: Dong Hui Inventor after: Wang Song Inventor after: Wang Xie Inventor after: Tian Deyong Inventor before: Wang Fang |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170630 Address after: 430030, Zhenxing Avenue, Dongxihu District, Hubei, Wuhan province 1 Applicant after: Wuhan Jun An Pharmaceutical Co., Ltd. Address before: 200040 Shanghai Pharmaceutical Industry Research Institute, No. 1320 West Beijing Road, Shanghai, Jingan District Applicant before: Wang Fang |
|
GR01 | Patent grant | ||
GR01 | Patent grant |